...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Genetic variability of the fructosamine 3-kinase gene in diabetic patients.
【24h】

Genetic variability of the fructosamine 3-kinase gene in diabetic patients.

机译:果糖胺3-激酶基因在糖尿病患者中的遗传变异性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Nonenzymatic glycation appears to be an important factor in the pathogenesis of diabetic complications. Fructosamine 3-kinase (FN3K), initially identified in erythrocytes, appears to be responsible for the removal of fructosamine from proteins, suggesting a protective role in nonenzymatic glycation. Recently, genetic variants in the FN3K gene have been studied in diabetic patients. The aim of our study was the molecular characterization of the FN3K gene in a representative group of Italian patients with type 1 (T1DM) and 2 (T2DM) diabetes mellitus and in a cohort of healthy controls. METHODS: Seventy diabetic subjects (35 type 1 and 35 type 2) with stable glycemic control and 33 healthy control subjects were evaluated using PCR and direct sequencing of the FN3K gene. Denaturing high performance liquid chromatography (DHPLC) was used in controls for screening for the presence of the genetic variants previously found in diabetic patients. RESULTS: Seven different genetic variants were identified, five of them already reported and two new: the p.R187X and p.Y239C mutations identified in two females affected by T2DM. No significant association was found between certain polymorphisms and diabetes conditions. Preliminary haplotype studies are also reported. With respect to genotypes, we noted that some were not present in all the investigated cohort, and some were found related to higher glycated hemoglobin compared to others, although not at a significant level, probably because of the small number of subjects investigated. CONCLUSIONS: In conclusion, this study identified two new mutations and additional variants within the FN3K gene. This is the first study on FN3K in Italy. Future work is needed to achieve a better understanding of the FN3K enzyme and its possible clinical utility in the management of diabetic patients.
机译:背景:非酶糖基化似乎是糖尿病并发症发病机制中的重要因素。果糖胺3激酶(FN3K)最初在红细胞中鉴定,似乎负责从蛋白质中去除果糖胺,提示在非酶糖基化中起保护作用。最近,已经在糖尿病患者中研究了FN3K基因的遗传变异。我们研究的目的是在一组意大利典型的1型(T1DM)和2型(T2DM)糖尿病患者以及一组健康对照组中FN3K基因的分子表征。方法:采用PCR和FN3K基因直接测序方法评估了70名血糖控制稳定的糖尿病患者(35例1型和35例2型)和33例健康对照者。变性高效液相色谱法(DHPLC)用于对照中,以筛选先前在糖尿病患者中发现的遗传变异体。结果:鉴定出七个不同的遗传变异,其中五个已经报告,两个新的:在两名受T2DM影响的雌性中鉴定出p.R187X和p.Y239C突变。在某些多态性与糖尿病状况之间未发现显着关联。还报道了单倍型的初步研究。关于基因型,我们注意到,在所有研究的队列中均未发现某些基因,与其他糖相比,糖化血红蛋白含量更高,尽管水平不高,可能是由于研究的受试者人数少。结论:总的来说,这项研究在FN3K基因中鉴定出两个新的突变和其他变异。这是意大利对FN3K的首次研究。需要进一步的工作来更好地了解FN3K酶及其在糖尿病患者管理中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号